The FDA's rejection of Depomed's (DEPO +6.2%) Sefelsa appears to be a non-event. Results of the...

|About: Depomed Inc. (DEPO)|By:, SA News Editor

The FDA's rejection of Depomed's (DEPO +6.2%) Sefelsa appears to be a non-event. Results of the FDA panel actually came out in early March, in which the majority voted against approval (13-1 against sufficient evidence of efficacy, 12-2 against risk/benefit profile).